Where does current and future pediatric asthma treatment stand? Remodeling and inflammation: Bird’s eye view.

Where does current and future pediatric asthma treatment stand? Remodeling and inflammation: Bird’s eye view.

Pediatr Pulmonol. 2016 May 27;

Authors: Yilmaz O, Yuksel H

Abstract
Airway remodeling is the chronic outcome of inflammation in asthma and a point of intervention between pediatric and adult ages. Pediatric asthma has been of great interest in the efforts to find a valuable time to interrupt remodeling. Various experimental and clinical research have assessed the effect of current therapeutic modalities on airway remodeling in asthma and many new agents are being developed with promising results. The heterogeneity in the results of these studies may lie in the heterogeneity of pathogenesis leading to asthma and remodeling; underlying the need for individualized treatment of the unique pathogenetic characteristics of each child’s asthma. The aim of this review is to summarize the evidence about the influence of current and future therapeutic modalities in the concept of inflammation and remodeling in pediatric asthma. Pediatr Pulmonol. 2016; 9999:1-9. © 2016 Wiley Periodicals, Inc.

PMID: 27233079 [PubMed – as supplied by publisher]

View full post on pubmed: asthma

Mount Sinai, LifeMap add doctor view, EHR integration to ResearchKit asthma app – MobiHealthNews


MobiHealthNews

Mount Sinai, LifeMap add doctor view, EHR integration to ResearchKit asthma app
MobiHealthNews
Asthma Health by Mount Sinai The Icahn School of Medicine at Mount Sinai and LifeMap Solutions have updated the asthma app, called Asthma Health, that they created for ResearchKit, Apple's open source platform that helps researchers build medical …
Mount Sinai and LifeMap Solutions announce initial results for asthma health appMedical Xpress
Mount Sinai and LifeMap Solutions Announce Initial Results for Asthma Health Newswise (press release)
Asthma app moves from research to realitymHealthNews

all 8 news articles »

View full post on asthma – Google News

US pulmonologists view refractory asthma patient treatment with biosimilar … – The Pharma Letter

US pulmonologists view refractory asthma patient treatment with biosimilar
The Pharma Letter
US pulmonologists surveyed by health care advisory firm Decision Resources estimate that only 19% percent of their severe, refractory asthma patients are treated with Genentech and Novartis' Xolair (omalizumab), the only approved drug that serves this

View full post on asthma – Google News